PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fostamatinib→

Fostamatinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
901119-35-5
Molecular formula
C23H26FN6O9P
Molecular weight
580.5 g/mol
Drug class
Spleen tyrosine kinase (SYK) inhibitorimmunomodulatory small molecule
Mechanism of action
Fostamatinib is converted to the active metabolite R406, which inhibits SYK signalling downstream of Fc receptors in macrophages and other immune cells. This reduces antibody-mediated platelet phagocytosis in immune thrombocytopenia.
Indications / reported uses
  • Treatment of thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment

Sources: US DailyMed — TAVALISSE (fostamatinib) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fostamatinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fostamatinib Permitted Daily Exposure (PDE) report (the Fostamatinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fostamatinib Occupational Exposure Limit (OEL) report (the Fostamatinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.